Press Releases and Blog
Blog
ICYMI: Economic Experts Explain the Misunderstood Role of Pharmacy Benefit Managers
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re
Senator Rand Paul Sounds the Alarm on Legislation Targeting Pharmacy Benefits that will Actually Increase Prescription Drug Prices
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case
New Brookings Analysis Concludes Legislation Targeting Pharmacy Benefit Companies Will Not Lower Prescription Drug Costs and Actually Weakens Negotiating Power Against Big Pharma
In case you missed it, the Brookings Institution released a new analysis, “A Brief Look At Current Debates About Pharmacy Benefit Managers,” which provides an
ICYMI: PCMA Rx Research Corner Blog Post: Dr. Lawton Robert Burns Sheds Light on the Role of PBMs
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton
ICYMI: Pharmacy Benefit Managers Are Not To Blame For Rising Drug Prices
PCMA Urges Congress to Listen to Constituents and Address Rising Drug Prices In case you missed it, JC Scott, president and CEO of the Pharmaceutical
Press Releases
PCMA Statement on Medicare Part D Final Rule
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the final Contract Year 2023 Policy and Technical Changes to the
PCMA Calls for Expanding COVID-19 “Test to Treat” Protocols to Include Pharmacists
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement supporting the policy of one-stop COVID-19 testing and
New PCMA Podcast Highlights Importance of PBMs
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, today released a new episode, “The Importance of PBMs in Health Care Costs,” which highlights the
PCMA Statement on the Senate Finance Committee Hearing on Prescription Drug Prices in Medicare
(Washington D.C.) – Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s Senate Finance Committee hearing, “Prescription Drug Price Inflation:
PCMA Statement on the Pre-Approval Information Exchange Act
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement on H.R. 7008, the Pre-approval Information Exchange (PIE) Act:
PCMA Applauds Passage of Postal Service Reform Act
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the passage of the Postal Service Reform
New Episode Of “The Pharmacy Benefit” Podcast Discusses Why We Need Competition To Drive Down Prescription Drug Costs
Alex Brill and Angela Banks Dive into the Critical Need for Competition, Big Drug Companies’ Abuse of the Patent System, and Biosimilar Adoption In case
Small And Mid-Sized Employers Rely On Spread Pricing For Predictable, Fixed Pricing
Pharmacy Benefit Companies Provide Employers with Coverage Choices and Flexibilities t hat Work for their Unique Needs Pharmacy benefit companies offer employers, including small and
Rebates Secured by Pharmacy Benefit Companies Result in Savings for Patients and Employers — and Have No Correlation to High Drug Prices
Pharmacy benefit companies push big drug companies for price concessions through rebates. 99.6 percent of rebates get passed directly to Medicare Part D plans, and
Expert Witness and Lawmakers Highlight Root Cause of High Rx Prices: Big Pharma’s Anti-Competitive Tactics
Hearing Confirms Big Drug Companies Would Benefit from Misguided Proposals Targeting Pharmacy Benefits This week, the U.S. House Committee on Oversight and Accountability held a
Pharmacy Benefit Companies Lower Rx Costs and Provide Critical Flexibility for Employers and Labor Unions
The evidence is clear: pharmacy benefit companies lower prescription drug costs for employers, labor union plans, taxpayers, and patients. While big drug companies push a
Expert Witness and Lawmakers Highlight Root Cause of High Rx Costs – Big Drug Companies’ Anti-Competitive Tactics
Last week, the U.S. House Ways and Means Committee Health Subcommittee held a hearing on “Why Health Care is Unaffordable: Anticompetitive and Consolidated Markets.” During
Pharmacy Benefit Companies Highlight Critical Role of Making Insulin Affordable and Accessible for All Americans at Senate Hearing
Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor
Market Forces Working to Lower Insulin Costs
Encouraging Signs that the Insulin Affordability Battle is Improving This week, as congressional hearings focus on access to affordable insulins, it should be recognized that
New PCMA Rx Research Corner Blog: The PBM Marketplace is More Competitive, Not Less
This week, the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee considers legislation that would lower choice in the market by creating a one-size-fits
Health Care Investors Oppose Big Drug Companies’ Patent Abuse
In case you missed it, a new article in Inside Health Policy reported that “Investors for eight major drug companies will vote throughout the spring on 11